Tag: triple negative breast cancer

1. The 5-year OS rate for pembrolizumab vs placebo was 86.1% vs 81.7% with HR 0.51 (significant). 2. Immune-mediated adverse ...

Click here to read this study in NEJM. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced ...

1. The median progression-free survival was improved with the pooled subtyping-based therapy group compared to the control group (11.3 months ...

1. Progression-free survival was 4.1 months in the combination arm vs 2.2 months in the monotherapy arm with an HR ...

1. Progression-free survival was 4.1 months in the combination arm vs 2.2 months in the monotherapy arm with an HR ...

1. Overall pathologic complete response to treatment of triple-negative breast cancer with a non-anthracycline regimen was 58% 2. The estimated ...

1. There was some progression-free survival benefit in adding veliparib to cisplatin in patients who had homologous recombination DNA repair ...

Click to read this study in Journal of Clinical Oncology. 

1. Sacituzumab govitecan was shown to significantly increase overall survival in previously treated metastatic triple-negative breast cancer patients compared to ...

1. Sacituzumab govitecan was shown to significantly increase overall survival in previously treated metastatic triple-negative breast cancer patients compared to ...